Expanded Access: Ifinatamab deruxtecan (I-DXd, DS-7300a) for pretreated extensive-stage SCLC

Study Details

Full Title

Medical Access Program for Ifinatamab deruxtecan (I-DXd, DS-7300a) (DS7300-0001-EAP-MA)

Principal Investigator

Joel
Rivera Concepcion

Protocol Number

PRO00120633

NCT ID

NCT07535359

Phase

N/A

Enrollment Status

Open to Enrollment
ClinicalTrials.gov